John Maris

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi request reprint Neuroblastoma
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet 369:2106-20. 2007
  2. pmc CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation
    Alex J Carlisle
    Division of Oncology, Abramson Research Center, Children s Hospital of Philadelphia, ARC 907A, 3615 Civic Center Blvd, Philadelphia, Pennsylvania 19104 4399, USA
    Mol Cancer 8:126. 2009
  3. pmc Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
    John M Maris
    Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Pediatr Blood Cancer 55:26-34. 2010
  4. doi request reprint Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:42-8. 2008
  5. doi request reprint Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma
    John M Maris
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    Cancer Cell 15:5-6. 2009
  6. ncbi request reprint Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:581-7. 2008
  7. ncbi request reprint Screening for neuroblastoma: a resurrected idea?
    John M Maris
    Center for Childhood Cancer Research, Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lancet 371:1142-3. 2008
  8. pmc Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
    John M Maris
    Division of Oncology and the Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 358:2585-93. 2008
  9. ncbi request reprint ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas
    Qun Wang
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:1631-5. 2003
  10. pmc CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
    Tomoyuki Fujita
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    J Natl Cancer Inst 100:940-9. 2008

Detail Information

Publications79

  1. ncbi request reprint Neuroblastoma
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet 369:2106-20. 2007
    ..Finally, we discuss new approaches to treatment, including recently discovered molecular targets that might provide more effective treatment strategies with the potential for less toxicity...
  2. pmc CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation
    Alex J Carlisle
    Division of Oncology, Abramson Research Center, Children s Hospital of Philadelphia, ARC 907A, 3615 Civic Center Blvd, Philadelphia, Pennsylvania 19104 4399, USA
    Mol Cancer 8:126. 2009
    ....
  3. pmc Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
    John M Maris
    Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Pediatr Blood Cancer 55:26-34. 2010
    ..MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis...
  4. doi request reprint Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:42-8. 2008
    ..Sunitinib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with selectivity for PDGF receptors, VEGF receptors, FLT3, and KIT...
  5. doi request reprint Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma
    John M Maris
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    Cancer Cell 15:5-6. 2009
    ..report that Aurora A interacts with MYCN, a potent oncogene in human neuroblastoma, and sequesters it from proteolytic degradation. This surprising finding further enhances Aurora A's potential as a therapeutic target...
  6. ncbi request reprint Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:581-7. 2008
    ..This study was designed to screen for antitumor activity of AZD2171 against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  7. ncbi request reprint Screening for neuroblastoma: a resurrected idea?
    John M Maris
    Center for Childhood Cancer Research, Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lancet 371:1142-3. 2008
  8. pmc Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
    John M Maris
    Division of Oncology and the Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 358:2585-93. 2008
    ..Neuroblastoma is a malignant condition of the developing sympathetic nervous system that most commonly affects young children and is often lethal. Its cause is not known...
  9. ncbi request reprint ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas
    Qun Wang
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:1631-5. 2003
    ..These data suggest that transcriptional regulation of ID2 by the MycN oncoprotein is unlikely to be a seminal molecular event resulting in a highly malignant neuroblastoma phenotype...
  10. pmc CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
    Tomoyuki Fujita
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    J Natl Cancer Inst 100:940-9. 2008
    ..31 that encodes 23 genes. Based on mutation analysis, expression pattern, and putative function, we identified CHD5 as the best tumor suppressor gene candidate...
  11. ncbi request reprint High-resolution detection and mapping of genomic DNA alterations in neuroblastoma
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Genes Chromosomes Cancer 43:390-403. 2005
    ..Taking all of this together indicates that aCGH can accurately measure CNAs in the neuroblastoma genome and facilitate gene discovery efforts by high-throughput refinement of candidate loci...
  12. ncbi request reprint Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction
    Michael Morowitz
    Division of Oncology, Children s Hospital of Philadelphia, Pennsylvania 19104 4318, USA
    Mod Pathol 16:1248-56. 2003
    ....
  13. ncbi request reprint Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number
    Qun Wang
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4399, USA
    Cancer Res 66:6050-62. 2006
    ..Lead positional candidates for neuroblastoma suppressor genes can be inferred from these data, but the potential multiplicity of transcripts involved has significant implications for ongoing gene discovery strategies...
  14. ncbi request reprint Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
    ..Neuroblastoma is a childhood cancer with considerable morbidity and mortality. Tumor-derived biomarkers may improve risk stratification...
  15. pmc Copy number variation at 1q21.1 associated with neuroblastoma
    Sharon J Diskin
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, USA
    Nature 459:987-91. 2009
    ..These data demonstrate that inherited copy number variation at 1q21.1 is associated with neuroblastoma and implicate a previously unknown neuroblastoma breakpoint family gene in early tumorigenesis of this childhood cancer...
  16. pmc Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target
    Naomi J Balamuth
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer Res 70:2749-58. 2010
    ....
  17. pmc A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene
    Kristina A Cole
    Division of Oncology, Children s Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    Mol Cancer Res 6:735-42. 2008
    ..BCL2 and MYCN were identified as miR-34a targets and likely mediators of the tumor suppressor phenotypic effect. These data support miR-34a as a tumor suppressor gene in human neuroblastoma...
  18. pmc Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
    David T Teachey
    Divisions of Oncology and Hematology, Children s Hospital of Philadelphia, ARC 902, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Blood 108:1965-71. 2006
    ..We conclude that rapamycin is an effective treatment for murine ALPS and should be explored as treatment for affected humans...
  19. ncbi request reprint Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma
    C Damodar Reddy
    Division of Neurosurgery, The Children s Hospital of Philadelphia and The Abramson Family Cancer Research Institute, Philadelphia, PA 19104, USA
    J Cell Biochem 97:198-206. 2006
    ..In summary, the low-calcemic hybrid analog QW showed significant anti-tumor activity in vivo and thus exhibits potential as a novel cancer therapeutic...
  20. ncbi request reprint Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Genes Chromosomes Cancer 46:936-49. 2007
    ..DNA signature patterns embed important prognostic information in diagnostic neuroblastoma samples, and can identify candidate cancer-related genes...
  21. pmc Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform
    John M Maris
    Division of Oncology, The Children s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genome Res 15:1168-76. 2005
    ....
  22. pmc STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
    Sharon J Diskin
    Division of Oncology, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Genome Res 16:1149-58. 2006
    ..We conclude that STAC is a powerful tool for identifying nonrandom genomic amplifications and deletions across multiple experiments. A Java version of STAC is freely available for download at http://cbil.upenn.edu/STAC...
  23. ncbi request reprint How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers
    John M Maris
    Children s Hospital of Philadelphia, PA 19104, USA
    Pediatr Blood Cancer 45:869-70. 2005
  24. ncbi request reprint CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data
    Adam A Margolin
    Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    Bioinformatics 21:3308-11. 2005
    ..It requires the installation of the free Java Runtime Environment 1.4.1 (or more recent) (http://www.java.sun.com)...
  25. ncbi request reprint Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13
    John M Maris
    Department of Pediatrics, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6651-8. 2002
    ..Taken together, these data suggest that a hereditary neuroblastoma predisposition gene (HNB1) is located at 16p12-13 and that disruption of this gene may contribute to the pathogenesis of nonfamilial neuroblastomas...
  26. ncbi request reprint Focus on embryonal malignancies
    John M Maris
    Division of Oncology, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer Cell 2:447-50. 2002
  27. ncbi request reprint Chemotherapy for neuroblastoma: is it all or none?
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Pediatr Hematol Oncol 25:512-4. 2003
  28. ncbi request reprint Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma
    Roberto Accorsi
    Division of Nuclear Medicine and Department of Radiology, The Children s Hospital of Philadelphia, 34th and Civic Center Blvd, PA 19104, Philadelphia, USA
    Pediatr Radiol 33:688-92. 2003
    ..To evaluate (131)I-MIBG scintigraphic localization of xenotransplanted and spontaneously arising neuroblastomas in murine models of high-risk neuroblastoma...
  29. pmc Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study
    Rochelle Bagatell
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Clin Oncol 29:208-13. 2011
    ..This phase II study was conducted to determine the response rate associated with use of irinotecan and temozolomide for children with relapsed/refractory neuroblastoma...
  30. ncbi request reprint Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma
    Tammy I Kang
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4318, USA
    J Pediatr Hematol Oncol 25:769-73. 2003
    ..This study was designed to retrospectively determine the clinical response to 131I-MIBG therapy at submyeloablative doses in patients with refractory neuroblastoma and to describe the toxicities...
  31. ncbi request reprint Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
    Peter S White
    Division of Oncology, The Children s Hospital of Philadelphia, 3516 Civic Center Blvd, Philadelphia, PA 19104, USA
    Oncogene 24:2684-94. 2005
    ..Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region...
  32. pmc Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104 4318, USA
    Genome Res 19:276-83. 2009
    ....
  33. ncbi request reprint The biologic basis for neuroblastoma heterogeneity and risk stratification
    John M Maris
    The Children s Hospital of Philadelphia, Division of Oncology, University of Pennsylvania School of Medicine, The Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Curr Opin Pediatr 17:7-13. 2005
    ..This review will describe the genetic and biologic basis for the diverse clinical phenotypes observed in neuroblastoma patients. It will also discuss the current approach to risk classification and how this may change in the future...
  34. pmc Identification of ALK as a major familial neuroblastoma predisposition gene
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 455:930-5. 2008
    ....
  35. ncbi request reprint No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3
    Michael D Hogarty
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6481-4. 2002
    ..58). These data strongly refute a parent-of-origin effect for 1p deletions in NB and exclude the existence of an imprinted NB suppressor locus in this region...
  36. pmc Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms
    Sharon J Diskin
    Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Nucleic Acids Res 36:e126. 2008
    ..With the wide application of whole-genome SNP genotyping techniques, our wave adjustment method will be important for taking full advantage of genotyped samples for CNV analysis...
  37. pmc Effect of sleep stage on breathing in children with central hypoventilation
    Jingtao Huang
    Sleep Center, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Appl Physiol 105:44-53. 2008
    ..The hypoventilation in CHS is more severe during NREM than REM sleep. We speculate that this may be due to increased excitatory inputs to the respiratory system during REM sleep...
  38. pmc Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
    Mario Capasso
    Division of Genetics, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Nat Genet 41:718-23. 2009
    ..We also found significant association with known BARD1 nonsynonymous SNPs. These data show that common variation in BARD1 contributes to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma...
  39. ncbi request reprint Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Blvd, Philadelphia, PA 19104 4318, USA
    Cancer Lett 228:83-90. 2005
    ....
  40. pmc A hidden Markov random field model for genome-wide association studies
    Hongzhe Li
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Biostatistics 11:139-50. 2010
    ..We demonstrate the application of the proposed HMRF model using data from a case-control GWAS of neuroblastoma and identify 1 new SNP that is potentially associated with neuroblastoma...
  41. ncbi request reprint Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor
    Ruth Ho
    Division of Oncology, Children s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 65:9868-75. 2005
    ..Our results also indicate that ZD1839 is a potent inhibitor of neuroblastoma cell proliferation; therefore, it may be a useful, biologically based therapeutic agent for these tumors...
  42. ncbi request reprint Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma
    Marc P Hickeson
    The Children s Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104, USA
    Pediatr Blood Cancer 42:268-74. 2004
    ..To evaluate the biodistribution of therapeutic (131)I-metaiodobenzylguanidine (MIBG) and assess the sensitivity of diagnostic versus therapeutic (131)I-MIBG scans to detect metastatic disease...
  43. pmc Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma
    Radhika Iyer
    Division of Oncology and Biostatistics and Data Management Core, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 16:1478-85. 2010
    ..We wanted to determine if the Trk-selective inhibitor lestaurtinib had therapeutic efficacy in a preclinical neuroblastoma model...
  44. ncbi request reprint Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma
    Christina M Coughlin
    Abramson Family Cancer Research Institute, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 24:5725-34. 2006
    ..In this study, our goal was to characterize the physiology of tumor immunosurveillance in children with high-risk neuroblastoma (HR-NBL)...
  45. doi request reprint Proton versus photon radiation therapy for patients with high-risk neuroblastoma: The need for a customized approach
    Christine Hill-Kayser
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 60:1606-11. 2013
    ..Proton therapy for treatment for high-risk neuroblastoma may offer sparing of organs at risk (OAR) when compared to intensity-modulated X-ray therapy (IMXT)...
  46. doi request reprint Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status
    Cynthia Winter
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:10-6. 2008
    ..While highly expressed on neuroblastoma cells, the relative contribution of the three major NCAM isoforms (120, 140, and 180 kDa) to neuroblastoma biology has not been investigated...
  47. ncbi request reprint Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma
    Yael Mosse
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet Oncol 4:769-71. 2003
  48. pmc Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndrome
    Jingtao Huang
    The Sleep Center, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Am J Respir Crit Care Med 178:757-64. 2008
    ..The ability of patients with central hypoventilation syndrome (CHS) to produce and process mechanoreceptor signals is unknown...
  49. ncbi request reprint Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions
    Nicholas R Mahoney
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Am J Ophthalmol 142:651-9. 2006
    ..To evaluate the frequency of etiologies of Horner syndrome in children and suggest an imaging and laboratory diagnostic protocol to evaluate for neuroblastoma and other lesions in a child presenting with Horner syndrome and no known cause...
  50. doi request reprint Inhibition of ALK signaling for cancer therapy
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Clin Cancer Res 15:5609-14. 2009
    ..The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations...
  51. pmc Germline PHOX2B mutation in hereditary neuroblastoma
    Yael P Mosse
    Am J Hum Genet 75:727-30. 2004
  52. doi request reprint Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  53. doi request reprint Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
    E Anders Kolb
    Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1190-7. 2008
    ..The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  54. ncbi request reprint Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma
    James P Howard
    Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Children s Hospital, San Francisco, California, USA
    Pediatr Blood Cancer 44:232-9. 2005
    ..Toxicity is mainly limited to myelosuppression. The aim of this study was to determine the response rate and hematologic toxicity of multiple infusions of (131)I-MIBG...
  55. pmc High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma
    Erik Fredlund
    Center for Molecular Pathology, Department of Laboratory Medicine, CREATE Health, University Hospital MAS, Lund University, SE 205 02 Malmo, Sweden
    Proc Natl Acad Sci U S A 105:14094-9. 2008
    ..These data suggest that pathway-specific gene expression profiling might be useful in the clinic to adjust treatment strategies for children with neuroblastoma...
  56. ncbi request reprint Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features
    Tatsuro Tajiri
    Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Clin Cancer Res 9:3345-55. 2003
    ..To determine the functional significance of BIN1 expression we ectopically expressed BIN1 isoforms in NB cell lines with and without MYCN amplification, and assessed clonogenic growth...
  57. ncbi request reprint Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models
    Michael J Morowitz
    Division of Oncology, Department of Pathology, The Children s Hospital of Philadelphia, PA, USA
    Clin Cancer Res 11:2680-5. 2005
    ..The potential for a wide therapeutic index may allow for treatment strategies that integrate MetAP2 inhibition with conventional cytotoxic compounds...
  58. ncbi request reprint Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2
    Jieyi Wang
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, Abbott Park, IL 60064, USA
    Cancer Res 63:7861-9. 2003
    ..These data affirm that MetAP2 plays a pivotal role in cell growth and establish that reversible MetAP2 inhibitors are promising novel cancer therapeutic agents...
  59. ncbi request reprint Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 22:2452-60. 2004
    ..The goal of this study was to determine risk factors for myelosuppression and the need for AHSCT after (131)I-MIBG treatment...
  60. ncbi request reprint Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 64:8816-20. 2004
    ..Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy...
  61. ncbi request reprint Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
    Lisa A Moreau
    The National Center for Pediatric Cancer Genetics, Children s Oncology Group, University of Florida, Gainesville, FL, USA
    Clin Cancer Res 12:5693-7. 2006
    ..The aim of this study was to determine whether children with neuroblastoma in which MYCN oncogene amplification is manifested as HSRs at diagnosis have a worse prognosis than those whose tumors exhibit dmins...
  62. ncbi request reprint Prospects for therapeutic inhibition of neuroblastoma angiogenesis
    Suzanne Shusterman
    Department of Pediatric Oncology, The Dana Farber Cancer Institute, Harvard Medical School, USA
    Cancer Lett 228:171-9. 2005
    ....
  63. ncbi request reprint Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study
    Rani E George
    Department of Pediatric Hematology and Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6466-73. 2005
    ..To determine predictive strength of tumor cell ploidy and MYCN gene amplification on survival of children older than 12 months with disseminated neuroblastoma (NB)...
  64. ncbi request reprint The pediatric preclinical testing program: description of models and early testing results
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 49:928-40. 2007
    ..Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide...
  65. ncbi request reprint Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California at San Francisco, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 25:1054-60. 2007
    ..To evaluate the effect of disease sites and prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neuroblastoma...
  66. ncbi request reprint Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:37-45. 2008
    ..The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  67. ncbi request reprint High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma
    Raymond L Stallings
    Children s Cancer Research Institute and Department of Pediatrics, University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Cancer Res 66:3673-80. 2006
    ..The most frequent microdeletion involved the PTPRD locus, indicating a possible tumor suppressor function for this gene...
  68. ncbi request reprint Initial testing of cisplatin by the pediatric preclinical testing program
    Mimi Tajbakhsh
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 50:992-1000. 2008
    ..Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts...
  69. ncbi request reprint Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
    Julia A Messina
    Department of Pediatrics, University of California, San Francisco, California 94143, USA
    Pediatr Blood Cancer 47:865-74. 2006
    ..The purpose of this study was to determine the accuracy of two semi-quantitative scoring systems to assess response to (131)I-metaiodobenzylguanidine (mIBG) therapy in recurrent neuroblastoma...
  70. ncbi request reprint Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:799-805. 2008
    ..Here we report the activity of rapamycin against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  71. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma...
  72. ncbi request reprint Initial testing of dasatinib by the pediatric preclinical testing program
    E Anders Kolb
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1198-206. 2008
    ..Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia...
  73. ncbi request reprint Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
    Richard Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 50:1181-9. 2008
    ....
  74. doi request reprint Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland
    Pediatr Blood Cancer 51:34-41. 2008
    ..Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival...
  75. ncbi request reprint Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study
    Mary Lou Schmidt
    Department of Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA
    J Clin Oncol 23:6474-80. 2005
    ..The long-term survival of children between age 12 and 24 months with stage 4 neuroblastoma and nonamplified MYCN (MYCN-NA) has not been defined previously...
  76. ncbi request reprint The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma
    Jun Fang
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Pharmacol 70:2108-15. 2006
    ..Such treatment would have selectivity by virtue of the acidic milieu surrounding tumors, because MCT is increasingly active as extracellular pH decreases below 7.0 and lactic acid production increases...
  77. ncbi request reprint Prominent microvascular proliferation in clinically aggressive neuroblastoma
    Radhika Peddinti
    Department of Pediatrics, Children s Memorial Hospital, Chicago, Illinois, USA
    Clin Cancer Res 13:3499-506. 2007
    ....
  78. pmc The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor
    Susanne Schlisio
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 22:884-93. 2008
    ....
  79. pmc The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor
    Wook Jin
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD 20892 5055, USA
    Proc Natl Acad Sci U S A 102:16239-44. 2005
    ..Our findings provide evidence for a previously undescribed mechanism by which oncogenic tyrosine kinases can block TGF-beta tumor suppressor activity...

Research Grants18

  1. The Genetic Basis of Neuroblastoma Tumorigenesis
    John Maris; Fiscal Year: 2009
    ..These insights will lead to new molecular diagnostic assays and/or new treatments for this frequently devastating malignancy of young children. ..
  2. Significance of Genetic Alterations in Neuroblastoma
    John Maris; Fiscal Year: 2006
    ..It is expected that these will be of prognostic importance and serve as specific targets for developmental therapeutics. ..
  3. ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE
    John Maris; Fiscal Year: 2006
    ..Ultimately, these experiments should lead to the identification of a common pathway to neuroblastoma tumorigenesis that will be an outstanding target for rationally designed therapeutics. ..
  4. ISOLATION OF THE NEUROBLASTOMA PREDISPOSITION GENE
    John Maris; Fiscal Year: 2002
    ..The successful completion of these studies should have considerable impact on the diagnosis and management of all children with neuroblastoma, a malignancy for which no causal genetic alterations have been identified. ..
  5. The Genetic Basis of Neuroblastoma Tumorigenesis
    John M Maris; Fiscal Year: 2010
    ..abstract_text> ..